JP2022551458A5 - - Google Patents

Info

Publication number
JP2022551458A5
JP2022551458A5 JP2022521144A JP2022521144A JP2022551458A5 JP 2022551458 A5 JP2022551458 A5 JP 2022551458A5 JP 2022521144 A JP2022521144 A JP 2022521144A JP 2022521144 A JP2022521144 A JP 2022521144A JP 2022551458 A5 JP2022551458 A5 JP 2022551458A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hantavirus
rodent
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551458A (ja
JP7802365B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/078104 external-priority patent/WO2021069486A1/en
Publication of JP2022551458A publication Critical patent/JP2022551458A/ja
Publication of JP2022551458A5 publication Critical patent/JP2022551458A5/ja
Application granted granted Critical
Publication of JP7802365B2 publication Critical patent/JP7802365B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521144A 2019-10-08 2020-10-07 ハンタウイルス感染症の処置のためのmek阻害剤 Active JP7802365B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LULU101430 2019-10-08
LU101430 2019-10-08
EP19203601.0 2019-10-16
EP19203601 2019-10-16
PCT/EP2020/078104 WO2021069486A1 (en) 2019-10-08 2020-10-07 Mek inhibitors for the treatment of hantavirus infections

Publications (3)

Publication Number Publication Date
JP2022551458A JP2022551458A (ja) 2022-12-09
JP2022551458A5 true JP2022551458A5 (cg-RX-API-DMAC7.html) 2023-10-17
JP7802365B2 JP7802365B2 (ja) 2026-01-20

Family

ID=73037924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521144A Active JP7802365B2 (ja) 2019-10-08 2020-10-07 ハンタウイルス感染症の処置のためのmek阻害剤

Country Status (10)

Country Link
US (1) US12661331B2 (cg-RX-API-DMAC7.html)
EP (1) EP4041212B1 (cg-RX-API-DMAC7.html)
JP (1) JP7802365B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079573A (cg-RX-API-DMAC7.html)
CN (1) CN114786659B (cg-RX-API-DMAC7.html)
AU (1) AU2020362953B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022005896A2 (cg-RX-API-DMAC7.html)
ES (1) ES3045883T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022004259A (cg-RX-API-DMAC7.html)
WO (1) WO2021069486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN116585294B (zh) * 2023-06-05 2025-06-17 中国人民解放军空军军医大学 大黄素在制备抗汉滩病毒药物中的应用
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CN101461805B (zh) * 2009-01-16 2010-07-28 武汉大学 一种抗汉坦病毒药物阿比朵尔的用途
CN109276716B (zh) 2012-10-08 2021-06-08 归属疗法有限公司 用在病毒性疾病的治疗中的mek抑制剂
EP3142658B1 (en) 2014-05-16 2020-01-15 Atriva Therapeutics GmbH Novel anti-infective strategy against influenza virus and s. aureus coinfections
DE102014111892A1 (de) 2014-08-20 2016-02-25 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer Infektion mit dem Hantavirus
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb

Similar Documents

Publication Publication Date Title
CN114786659B (zh) 用于治疗汉坦病毒感染的mek抑制剂
DK1982708T3 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanediol derivative as active ingredient and method of treating inflammatory bowel disease
US20220125767A1 (en) Thiazolide compounds for treating viral infections
JP2020537659A (ja) ウイルス感染および細菌感染の処置のための新規mek阻害剤
Rebeaud et al. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
CN115916162A (zh) 用于冠状病毒治疗的吡非尼酮
KR20210120891A (ko) 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물
JP2022529343A (ja) ウイルス感染および細菌感染の治療のための新規mek阻害剤
JP2022546424A5 (cg-RX-API-DMAC7.html)
WO2022020967A1 (en) Use of wnt/beta-catenin pathway inhibitors to block replication of sars-cov-2 and other pathogenic viruses
ES2937145T3 (es) Azelastina como tratamiento antiviral
EP4431103A1 (en) Formulations comprising heparan sulfate for the treatment and prevention of viral infections caused by orthocoronaviridae
EP4527410A1 (en) Composition for inhibiting coronaviruses or enteroviruses
CA3152450C (en) Mek inhibitors for the treatment of hantavirus infections
IT201600074507A1 (it) Uso di xibornolo come agente attivo nel trattamento di infezioni virali
Ticotosti et al. Disseminated Strongyloidiasis in Patients Diagnosed with COVID-19 Treated with Corticoids
HK40081976B (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease
JP2011530585A5 (cg-RX-API-DMAC7.html)
Castro The role of reactive oxygen species as mediators of respiratory syncytial virus induced pulmonary inflammation